

EDITOR'S PAGE

- 1329** The Future of Nuclear Medicine
David Mankoff

CONTINUING EDUCATION

- 1331** New Developments in Myeloma Treatment and Response Assessment
Françoise Kraeber-Bodéré, Bastien Jamet, Davide Bezzi, Elena Zamagni, Philippe Moreau, and Cristina Nanni

FOCUS ON MOLECULAR IMAGING

- 1344** Marshalling the Potential of Auger Electron Radiopharmaceutical Therapy
Julie Bolcaen, Mohamed A. Gizawy, Samantha Y.A. Terry, António Paulo, Bart Cornelissen, Aruna Korde, Jonathan Engle, Valery Radchenko, and Roger W. Howell

ISSUES AND CONTROVERSIES

- 1352** The Future of Nuclear Medicine in the United States
Michael M. Graham
- 1354** ■ **INVITED PERSPECTIVE.** The Future of Nuclear Medicine in the United States
George M. Segall, Maria Watts, and Kirk A. Frey
- 1356** ■ **INVITED PERSPECTIVE.** Stronger Together—Collaboration Will Only Enhance Patient Care
Erin E. Grady, David A. Mankoff, and David M. Schuster
- 1359** ■ **INVITED PERSPECTIVE.** Redesigned Curricula, Stringent Licensing Criteria, and Integrated Independence Are Conditions for a Bright Future for Nuclear Medicine in the United States
Johannes Czernin and Jeremie Calais

DISCUSSIONS WITH LEADERS

- 1361** Toward Integrated Independence: Johannes Czernin Discusses the Future of Theranostics with Ebrahim Delpassand, Eric Rohren, and Wolfgang Weber
Ebrahim S. Delpassand, Eric M. Rohren, Wolfgang A. Weber, and Johannes Czernin

ONCOLOGY

Clinical

- 1364** ■ **FEATURED ARTICLE OF THE MONTH.** Human Epidermal Growth Factor Receptor 2-Targeting [⁶⁸Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer
Ali Alhuseinalkhudhur, Henrik Lindman, Per Liss, Tora Sundin, Fredrik Y. Frejd, Johan Hartman, Victor Iyer, Joachim Feldwisch, Mark Lubberink, Caroline Rönnlund, et al.

- 1371** [¹⁸F]FDG PET/CT in the Initial Staging and Restaging of Soft-Tissue or Bone Sarcoma in Patients with Negative or Equivocal Findings for Metastases or Limited Recurrence on Conventional Work-up: Results of a Prospective Multicenter Registry
Ur Metsers, Roshini Kulanthaivelu, Abdulzeez Salawu, Albiruni Razak, Victor Mak, Xuan Li, Deanna L. Langer, Pamela MacCrostie, and Amit Singunkar

- 1378** Phase I Study of [⁶⁸Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)
Odrade Gondry, Catarina Xavier, Laurens Raes, Johannes Heemskerck, Nick Devoogdt, Hendrik Everaert, Karine Breckpot, Quentin Lecocq, Lore Decoster, Christel Fontaine, et al.

- 1385** Performance of ⁶⁸Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT in Evaluation of Erdheim-Chester Disease: A Comparison with ¹⁸F-FDG PET/CT
Jiangyu Ma, Qiao Yang, Li Huo, Jiawen Dai, Na Niu, and Xinxin Cao

- 1392** Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ²²³Ra: PARABO, a Prospective, Noninterventional Study
Holger Palmedo, Hojjat Ahmadzadehfar, Susanne Eschmann, Andreas Niesen, Johann Schönberger, Vahé Barsegian, Knut Liepe, Felix M. Mottaghy, Rongjin Guan, Joerg Pinkert, et al.

THERANOSTICS

Clinical

- 1399** Fibroblast Activation Protein and Glycolysis in Lymphoma Diagnosis: Comparison of ⁶⁸Ga-FAPI PET/CT and ¹⁸F-FDG PET/CT
Xuetao Chen, Shuailiang Wang, Yumei Lai, Guochang Wang, Maomao Wei, Xiao Jin, Jin Ding, Yan Zhang, Yunfei Shi, Feng Wang, et al.
- 1406** Head-to-Head Comparison of ⁶⁸Ga-NODAGA-JR11 and ⁶⁸Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: Interim Analysis of a Prospective Bicenter Study
Zefang Lin, Wenjia Zhu, Jiaying Zhang, Weibing Miao, Shaobo Yao, and Li Huo
- 1412** ■ **BRIEF COMMUNICATION.** The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to ¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy
Shejil Kumar, Megan Crumbaker, Christopher Harvey, Sarennya Pathmanandavel, Nikieth John, Mina M. Swiha, Michelle M. McDonald, Roderick Clifton-Bligh, Adrian Lee, Patricia Bastick, et al.
- 1417** ■ **PRACTICE STANDARDS.** SNMMI Consensus Statement on Patient Selection and Appropriate Use of ¹⁷⁷Lu-PSMA-617 Radionuclide Therapy
Thomas A. Hope, Emmanuel S. Antonarakis, Lisa Bodei, Jeremie Calais, Amir Iravani, Heather Jacene, Phillip J. Koo, Alicia K. Morgans, Joseph R. Osborne, Scott T. Tagawa, et al.

1424 CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell Tumors
Ingo Hartlapp, Philipp E. Hartrampf, Sebastian E. Serfling, Vanessa Wild, Alexander Weich, Leo Rasche, Sabine Roth, Andreas Rosenwald, Patrick W. Mihatsch, Anne Hendricks, et al.

1431 Dual-Time-Point Posttherapy ¹⁷⁷Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients' Outcome
Manuela Straub, Jürgen Kupferschläger, Lina Maria Serna Higueta, Matthias Weissinger, Helmut Dittmann, Christian la Fougère, and Francesco Fiz

Basic

1439 Efficacy of HER2-Targeted Intraperitoneal ²²⁵Ac α -Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis
Sebastian K. Chung, Daniela Burnes Vargas, Christopher S. Chandler, Sumudu Katugampola, Darren R. Veach, Michael R. McDevitt, Shin H. Seo, Brett A. Vaughn, Sara S. Rinne, Blesida Punzalan, et al.

1446 ■ INVITED PERSPECTIVE. Pretargeted Radioimmunotherapy of Ovarian Cancer with ²²⁵Ac and an Internalizing Antibody
Xiaoyan Li, Xiaoli Lan, and Weibo Cai

1449 Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy
Yizhen Pang, Liang Zhao, Jianyang Fang, Jianhao Chen, Lingxin Meng, Long Sun, Hua Wu, Zhide Guo, Qin Lin, and Haojun Chen

RADIOBIOLOGY/DOSIMETRY

Clinical

1456 Specific Uptake in the Bone Marrow Causes High Absorbed Red Marrow Doses During [¹⁷⁷Lu]Lu-DOTATATE Treatment
Jens Hemmingsson, Johanna Svensson, Andreas Hallqvist, Katja Smits, Viktor Johanson, and Peter Bernhardt

1463 Single-Time-Point Imaging for Dosimetry After [¹⁷⁷Lu]Lu-DOTATATE: Accuracy of Existing Methods and Novel Data-Driven Models for Reducing Sensitivity to Time-Point Selection
Chang Wang, Avery B. Peterson, Ka Kit Wong, Molly E. Roseland, Matthew J. Schipper, and Yuni K. Dewaraja

1471 Monte Carlo Simulations Corroborate PET-Measured Discrepancies in Activity Assessments of Commercial ⁹⁰Y Vials
Lucrezia Auditore, Daniele Pistone, Antonio Italiano, Ernesto Amato, and Silvano Gnesin

CARDIOVASCULAR

Clinical

1478 Temporal Changes in Coronary ¹⁸F-Fluoride Plaque Uptake in Patients with Coronary Atherosclerosis
Marwa Daghem, Philip D. Adamson, Kang-Ling Wang, Mhairi Doris, Rong Bing, Edwin J.R. van Beek, Laura Forsyth, Michelle C. Williams, Evangelos Tzolos, Damini Dey, et al.

Basic

1487 Multimodality Imaging of Aortic Valve Calcification and Function in a Murine Model of Calcific Aortic Valve Disease and Bicuspid Aortic Valve
Azmi A. Ahmad, Mean Ghim, Jakub Toczek, Afarin Neishabouri, Devi Ojha, Zhengxing Zhang, Kiran Gona, Muhammad Zawwad Raza, Jae-Joon Jung, Gunjan Kukreja, et al.

NEUROLOGY

Basic

1495 ■ FEATURED BASIC SCIENCE ARTICLE. Preclinical Characterization of the Tau PET Tracer [¹⁸F]SNFT-1: Comparison of Tau PET Tracers
Ryuichi Harada, Pradith Lerdsiriruk, Yuki Shimizu, Yuka Yokoyama, Yiqing Du, Kaede Kudo, Michinori Ezura, Yoichi Ishikawa, Ren Iwata, Miho Shidahara, et al.

ILLUSTRATED POST

1502 PSMA-Negative Lesion Progression Under ¹⁷⁷Lu-PSMA Radioligand Therapy
Vishnu Murthy, Martin Allen-Auerbach, Richard Lam, Dawn Owen, Johannes Czernin, and Jeremie Calais

DEPARTMENTS

8A This Month in JNM

1503 Erratum